Michael B. Atkins, MD

GU Oncology Now

<p>Michael B. Atkins, MD, of the Lombardi Comprehensive Cancer Center, discusses treatment-free survival outcomes from the phase 2 HCRN GU16-260 study and what the data tell us for immunotherapy applicability in favorable-risk patients.</p>


HCRN GU16-260: Nivolumab, Salvage Nivo/Ipi in Advanced Clear Cell RCC

American Society of Clinical Oncology Genitourinary Cancers Symposium 2023

ASCO GU Symposium 2023

Michael B. Atkins, MD, discusses TFS outcomes from the phase II study and what the data tells us for immunotherapy in favorable-risk patients.

HCRN GU16-260: Nivolumab, Salvage Nivo/Ipi in accRCC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe